Amphion Innovations reports interim results for the six months ended 30 June 2009

Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, today announces its unaudited interim results for the six months to 30 June 2009.

Highlights

• Net Asset Value per Share was approximately unchanged versus December 2008 at US $0.44, but down 15.38% since June 2008 (US $0.52). In sterling terms, the NAV per Share increased by 3.85% to £0.27 over the levels of June 2008 (£0.26), a 10% decrease since December 2008 (£0.30)
• Operating results improved sharply from a loss of over US $1.73 million in the first half of 2008, to very close to breakeven for the first half of 2009
• DataTern, Inc. signed 7 non-exclusive patent license agreements during the first half of 2009, with an additional license agreement concluded in July. In August, the United States Patent and Trademark Office found DataTern’s ‘502 patent valid for all 18 original claims and 26 new claims after re-examination. DataTern has now signed a total of 11 license agreements, bringing its total revenues since inception to approximately US $9.4 million
• Received a further subscription of £716,900 bringing the total to £3.5 million for Amphion’s Convertible Promissory Note, launched to support funding for Amphion and the Partner Companies

Amphion’s Chief Executive Officer, Richard Morgan, said:

“I am pleased to announce that Amphion has managed to weather the economic and financial storm of the last six months relatively well, with a near breakeven versus the US $1.73 million operating loss for the first half of 2008. We have also made good progress in the development of our IP licensing programme through DataTern, which has established itself as a significant source of revenue for Amphion. I am excited by the value that is being created in each of our Partner Companies and remain confident in the strength of the Amphion model.”